Welcome to our dedicated page for FENNEC PHARMACEUTICALS SEC filings (Ticker: FENC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Fennec Pharmaceuticals Inc. filings document formal disclosures for its commercial specialty pharmaceutical business, PEDMARK® product updates, and Nasdaq-listed common shares. Recent Form 8-K reports cover financial results, scientific presentations and investigator-sponsored studies involving sodium thiosulfate injection, and a license agreement resolving litigation tied to a proposed generic version of PEDMARK.
The company’s proxy materials cover director elections, board composition, executive compensation, equity awards, and shareholder voting matters. Other current reports disclose governance changes, registered common shares with no par value, and exhibits furnished with press releases concerning business, clinical, and product-related developments.
Fennec Pharmaceuticals Inc. received an amended Schedule 13G (Amendment No. 3) from a group of Southpoint-related entities and individual John S. Clark regarding its Common Shares, no par value. The reporting persons – Southpoint Master Fund, LP; Southpoint Capital Advisors LP; Southpoint Capital Advisors LLC; Southpoint GP, LP; Southpoint GP, LLC; and John S. Clark – each report 0 Common Shares beneficially owned, with 0% of the class and no sole or shared voting or dispositive power. They indicate they now hold ownership of 5 percent or less of the class. The filing is signed by John S. Clark II in multiple related capacities on August 14, 2026.
Solas Capital Management, LLC and Frederick Tucker Golden report beneficial ownership of Fennec Pharmaceuticals Inc. common shares. They each report 1,889,366 shares of common stock, representing 5.4% of the class, held through a fund and another private fund they manage. The percentage is based on 34,737,030 shares outstanding as of May 12, 2026. They report no sole voting or dispositive power, but shared voting and shared dispositive power over all 1,889,366 shares. The funds themselves expressly disclaim beneficial ownership of the reported securities under Rule 13d-4.
Fennec Pharmaceuticals reported strong growth and a shift to profitability driven by commercialization of PEDMARK®. For the quarter ended June 30, 2026, total revenue was $17.9 million, up from $9.7 million a year earlier, including PEDMARK net product sales of $17.2 million and $0.7 million of other revenue from its PEDMARQSI® license with Norgine.
Quarterly income from operations was $1.7 million versus a loss of $2.7 million, and net income was $2.0 million versus a net loss of $3.2 million. For the first six months of 2026, revenue reached $33.0 million, with net income of $2.2 million compared to a $4.3 million loss in 2025, and operating cash flow improved to $2.4 million.
Growth was accompanied by a sharp increase in selling and marketing expense to $10.7 million in the quarter, reflecting continued U.S. commercialization and support for international expansion through Norgine. Fennec ended June 30, 2026 with $41.2 million in cash and cash equivalents and $42.4 million of stockholders’ equity, and believes existing cash plus expected revenues will fund operations for at least the next twelve months.
Fennec Pharmaceuticals Inc. received an updated ownership report from Rosalind Advisors Inc. and related parties. They report beneficial ownership of up to 3,321,333 common shares, representing 9.6% of Fennec’s common stock, based on 34,737,030 shares outstanding as of May 12, 2026.
Rosalind Master Fund L.P. holds 3,188,001 shares with shared voting and dispositive power, while Steven Salamon and Gilad Aharon each have sole voting and dispositive power over 66,666 shares plus shared power over 3,188,001 shares. Rosalind Advisors and Mr. Salamon may be deemed beneficial owners but both disclaim beneficial ownership.
FENNEC PHARMACEUTICALS INC. reported that former director Rosty Raykov sold 10,000 common shares on 2026-08-03 at $9.5800 per share in a sale classified as an open-market or private transaction. The sale was executed under a Rule 10b5-1 plan dated September 19, 2025, and left him holding 131,633 common shares directly.
FENC shareholder Rostislav Raykov filed to sell 10,000 shares of common stock through Morgan Stanley Smith Barney LLC on or after 08/03/2026 on NASDAQ. The shares were acquired as Restricted Stock from the issuer on 11/30/2025, and prior sales in the last three months totaled 19,346 shares.
Fennec Pharmaceuticals Inc. reported that Chief Medical Officer Pierre Sargis Sayad acquired 168 Common Shares on July 31, 2026 through a release of restrictions on shares originally awarded on March 28, 2025. The award had a stated per-share price of $0.00, increasing his direct ownership to 21,351 Common Shares.
Fennec Pharmaceuticals reported that Chief Commercial Officer Terry L. Evans acquired 168 Common Shares on July 31, 2026 through the release of restrictions on shares originally awarded 3/28/2025. After this vesting event, Evans directly holds 21,351 Common Shares, with no Rule 10b5-1 trading plan indicated.
Fennec Pharmaceuticals Inc. reported that Chief Strategy Officer Christiana Marie Cioffi acquired 156 common shares on July 31, 2026 through the release of restrictions on shares awarded March 28, 2025 at a stated price of $0.0000 per share. After this compensation-related release, she directly holds 24,488 common shares.
Fennec Pharmaceuticals Chief Executive Officer Jeffrey S. Hackman acquired 1,159 Common Shares on July 31, 2026 through the release of restrictions on shares originally awarded on March 28, 2025. Following this equity compensation event, his direct holdings total 65,143 Common Shares at a reported transaction price of $0.0000 per share.